Prognostic Significance of Circulating Tumor Cell Count in Patients With Metastatic Hormone-sensitive Prostate Cancer
- 1 December 2012
- Vol. 80 (6), 1328-1332
- https://doi.org/10.1016/j.urology.2012.09.001
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate CancerClinical Genitourinary Cancer, 2011
- Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic FactorsCancer Epidemiology, Biomarkers & Prevention, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experienceAnnals of Oncology, 2008
- Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007
- Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 2007
- Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007
- Circulating tumor cells predict survival in patients with metastatic prostate cancerUrology, 2005
- Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced diseaseUrology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004